Predictors of Response to Anti-Il6 Monoclonal Antibody Therapy (Siltuximab) in Idiopathic Multicentric Castleman Disease: Secondary Analyses of Phase II Clinical Trial Data

British Journal of Haematology - United Kingdom
doi 10.1111/bjh.15588
Full Text
Abstract

Available in full text

Categories
Hematology
Date
Authors
Publisher

Wiley

Related search

Siltuximab: A Targeted Therapy for Idiopathic Multicentric Castleman Disease

Immunotherapy
OncologyAllergyImmunology
2016English

FDA Approval: Siltuximab for the Treatment of Patients With Multicentric Castleman Disease

Clinical Cancer Research
Cancer ResearchOncology
2015English

Long-Term Safety of Siltuximab in Patients With Idiopathic Multicentric Castleman Disease: A Prespecified, Open-Label, Extension Analysis of Two Trials

The Lancet Haematology
Hematology
2020English

Biologic Agents in the Treatment of Multicentric Castleman Disease

Turkish Thoracic Journal
PulmonaryRespiratory Medicine
2018English

Multicentric Castleman Disease: An Unusual Breast Lump

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2009English

A Phase I-Ii Clinical Trial of the Anti-Cd74 Monoclonal Antibody Milatuzumab in Frail Patients With Refractory Chronic Lymphocytic Leukaemia: A Patient Based Approach

British Journal of Haematology
Hematology
2017English

Clinicopathologic Characteristics of 342 Patients With Multicentric Castleman Disease in Japan

Modern Rheumatology
MedicineRheumatology
2020English

Phase I Trial of Anti-Gd2 Monoclonal Antibody Hu3F8 Plus GM-CSF: Impact of Body Weight, Immunogenicity and Anti-Gd2 Response on Pharmacokinetics and Survival

OncoImmunology
OncologyAllergyImmunology
2017English

Monoclonal Antibody Therapy for Non-Malignant Disease

Australian Prescriber
Pharmacology
2006English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy